Page last updated: 2024-12-04

aminocaproic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Aminocaproic Acid: An antifibrinolytic agent that acts by inhibiting plasminogen activators which have fibrinolytic properties. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

6-aminohexanoic acid : An epsilon-amino acid comprising hexanoic acid carrying an amino substituent at position C-6. Used to control postoperative bleeding, and to treat overdose effects of the thrombolytic agents streptokinase and tissue plasminogen activator. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID564
CHEMBL ID1046
CHEBI ID16586
CHEBI ID79212
SCHEMBL ID15293
MeSH IDM0023260

Synonyms (303)

Synonym
MLS002695931
AC-035
BIDD:GT0162
CHEMBL1046
177 jd
177-jd
cl-10304
AB00051911-08
epsilon-ahx
1319-82-0
caproamin
acido aminocaproico
aminohexanoic acid
epsicaprom
acide aminocaproque
epsilon-amino-n-hexanoic acid
acidum aminocaproicum
epsilon-norleucine
omega-aminocaproic acid
CHEBI:16586 ,
epsilon-aminohexanoic acid
epsilon-leucine
omega-aminohexanoic acid
caprocid
177 j.d
.epsilon.-aminohexanoic acid
cl 10304
eacs
.omega.-aminohexanoic acid
nsc-26154
amikar
epsamon
epsilcapramin
epsilon s
ACS ,
hemocaprol
respramin
nsc26154
cy-116
cy116
afibrin
cy 116
epsikapron
hepin
hemopar
eaca
ipsilon
capranol
.epsilon. s
.omega.-aminocaproic acid
epsicapron
177 j.d.
.epsilon.-leucine
.epsilon.-aminocaproic acid
wln: z5vq
.epsilon.-norleucine
nsc212532
nsc-212532
KBIO1_000551
DIVK1C_000551
hsdb 3005
einecs 200-469-3
ai3-14512
acido aminocaproico [dcit,spanish]
jd 177
brn 0906872
eaca kabi
epsilon-aminocapronzuur
nsc 26154
acidum aminocaproicum [latin]
ccris 7706
epsilon-aminocapronsaeure
nsc 400230
kyselina omega-aminokapronova [czech]
aminocaproic
acide aminocaproique [french]
aminocaproic acid in plastic container
EU-0100082
6-aminocaproic acid, bioultra, >=99%
epsilon-aminocaproic acid (jan)
D00160
aminocaproic acid (usp/inn)
amicar (tn)
SPECTRUM_000038
lopac-a-7824
NCGC00015092-01
cas-60-32-2
NCGC00015092-02
CBDIVE_004370
LMFA01100035
6-amino-hexanoic acid
IDI1_000551
nsc400230
BSPBIO_000960
LOPAC0_000082
PRESTWICK3_000960
BPBIO1_001056
hexanoic acid,6-amino
inchi=1/c6h13no2/c7-5-3-1-2-4-6(8)9/h1-5,7h2,(h,8,9
nsc-400230
AB00051911
capracid
epsilon-aminocaproate
epsilon-amino-n-caproic acid
aminocaproic acid
e-amino-n-caproic acid
60-32-2
6-aminocaproic acid
caprolisin
capramol
acepramine
hexanoic acid, 6-amino-
6-amino-n-hexanoic acid
acepramin
epsilon-aminocaproic acid
atsemin
6-aminohexanoic acid
C02378
aminokapron
amicar
epsilcapramine
capralense
caplamin
6-aminocaproic acid, >=99% (titration), powder
DB00513
1CEA
3KIV
epsilon aminocaproic acid
NCGC00093587-03
NCGC00093587-02
KBIO2_000398
KBIO2_005534
KBIO2_002966
KBIOSS_000398
KBIOGR_000586
SPBIO_003109
PRESTWICK1_000960
SPECTRUM4_000143
NINDS_000551
PRESTWICK0_000960
SPBIO_000202
SPECTRUM2_000131
SPECTRUM1500114
SPECTRUM5_000780
PRESTWICK2_000960
NCGC00093587-04
NCGC00093587-01
MLS001335991
smr000059162
STK246894
NCGC00015092-03
HMS2091I07
6-aminocaproic acid; eaca
A 7824 ,
C3BDD377-8F43-4BEC-900A-D5850050BA82
A0312
NCGC00015092-07
AKOS000118734
acide aminocaproique [inn-french]
BMSE000394
aminocaproic acid [usan:ban:inn]
acidum aminocaproicum [inn-latin]
aminocaproic acid (usp)
acido aminocaproico [inn-spanish]
HMS501L13
HMS1570P22
HMS1920C07
A15677
HMS2097P22
HMS3260A06
u6f3787206 ,
aminocaproic acid [usan:usp:inn:ban]
acide aminocaproique
kyselina omega-aminokapronova
unii-u6f3787206
A-5295
pharmakon1600-01500114
nsc755867
nsc-755867
dtxcid7070
tox21_110081
dtxsid0020070 ,
e-aminocaproic acid
|a-ahx
|a-amino caproic acid
HMS2231F21
CCG-38935
NCGC00015092-06
NCGC00015092-05
NCGC00015092-04
bdbm50357211
BP-20395
NCGC00015092-09
LP00082
aminocaproic acid [vandf]
aminocaproic acid [ep impurity]
epsilon-aminocaproic acid [jan]
zinc acexamate impurity b [ep impurity]
aminocaproic acid [ep monograph]
aminocaproic acid [who-dd]
aminocaproic acid [usan]
6-aminocaproic acid [inci]
aminocaproic acid [hsdb]
aminocaproic acid [usp monograph]
.epsilon.-aminocaproic acid [mi]
aminocaproic acid [usp-rs]
.epsilon.-aminocaproic acid [jan]
aminocaproic acid [mart.]
aminocaproic acid [inn]
aminocaproic acid [orange book]
S1671
gtpl6574
HMS3373F09
FT-0620933
HY-B0236
AM82438
|a- aminocaproic acid
SCHEMBL15293
NCGC00015092-10
tox21_110081_1
KS-5276
CHEBI:79212
NCGC00260767-01
tox21_500082
6aminocaproic acid
nh2-(ch2)5-cooh
amino caproic
6-aca
epsilon-amino caproic acid
6-amino caproic acid
amino caproic acid
.epsilon.-amino-n-caproic acid
.epsilon.-amino-n-hexanoic acid
AB00051911_10
AB00051911_09
mfcd00008238
F2191-0201
aminocaproic acid, european pharmacopoeia (ep) reference standard
pound 6- pound(c)|a-?aminocaproic acid
SR-01000075688-1
sr-01000075688
6-aminohexanoic acid, >=98.5% (nt)
6-aminocaproic acid, saj special grade, >=99.0%
aminocaproic acid, united states pharmacopeia (usp) reference standard
HMS3655M17
e-amino-n-hexanoate
w-aminocaproate
w-aminocaproic acid
h-eahx-oh
e-aminohexanoic acid
e-aminohexanoate
epsilon-aminohexanoate
6-aminocaproate
e-norleucine
e-leucine
omega-aminocaproate
h-epsilon-acp-oh
acikaprin
e-amino-n-hexanoic acid
epsillon-aminocaproate
e-aminocaproic acid usp
epsilon-s
omega-aminohexanoate
6-amino-n-hexanoate
epsillon-aminocaproic acid
e-aminocaproate
h-6-ahx-oh
6-amino-hexanoate
w-aminohexanoic acid
w-aminohexanoate
epsilon-amino-n-hexanoate
P19609
aminocaproic acid, pharmaceutical secondary standard; certified reference material
z artifact
SR-01000075688-3
SR-01000075688-6
SBI-0050070.P004
HMS3714P22
SY003109
_6-__-_aminocaproic acid
SW197248-3
eaca;epsilon-amino-n-caproic acid;6-aminohexanoic acid
trifluoroacctic acid
BCP24729
aminocaproic acid (aminocaproic acid).
pound 6- pound(c)|a-aminocaproic acid
aminocaproic acid (amicar)
Q255968
acepramine; 6-amino-n-hexanoic acid; 6-aminocaproic acid; 6-aminohexanoic acid
epsillon-aminocaproic acid' epsilcapramin
epsilon-aminocaproic acid usp
BCP27495
h-acp-oh
h-acp(6)-oh
(6-)epsilon-aminocaproic acid
SDCCGSBI-0050070.P005
NCGC00015092-17
aminocaproic-acid
epsilon
A929179
3-propyl-2'-(n-methyl-n-ethynylamino)pyridine
PB43139
EN300-17983

Research Excerpts

Overview

ε-Aminocaproic acid (EACA) is a lysine analogue antifibrinolytic drug used to treat bleeding disorders in humans and domestic animals. It has been shown to decrease blood loss and transfusion requirements.

ExcerptReferenceRelevance
"ε-Aminocaproic acid (EACA) is an antifibrinolytic agent that has been shown to decrease blood loss and transfusion requirements in several populations undergoing various surgical procedures. "( Effect of Intravenous Aminocaproid Acid on Blood Loss and Transfusion Requirements After Bilateral Varus Rotational Osteotomy: A Double-blind, Placebo-controlled Randomized Trial.
Dodwell, E; Edmonds, C; Nguyen, J; Scher, D; Swarup, I, 2020
)
1.28
"ε-Aminocaproic acid (EACA) is a lysine analogue antifibrinolytic drug used to treat bleeding disorders in humans and domestic animals. "( EFFECT OF ε-AMINOCAPROIC ACID ON FIBRINOLYSIS IN PLASMA OF ASIAN ELEPHANTS (ELEPHAS MAXIMUS).
Abou-Madi, N; Fletcher, DJ; Kaye, S, 2016
)
1.53
"ε-Aminocaproic acid (EACA) is a lysine analogue antifibrinolytic drug used to treat bleeding disorders in humans and domestic animals. "( PHARMACOKINETIC STUDY OF ORAL ε-AMINOCAPROIC ACID IN THE NORTHERN ELEPHANT SEAL (MIROUNGA ANGUSTIROSTRIS).
Abou-Madi, N; Arnold, RD; Davis, JT; Fletcher, DJ; Gulland, F; Johnson, S; Kaye, S; Nie, B, 2016
)
1.44

Effects

Aminocaproic acid (ACA) has been used at our institution during CVR for its antifibrinolytic effects.

ExcerptReferenceRelevance
"Aminocaproic acid (ACA) has been used at our institution during CVR for its antifibrinolytic effects."( Minimizing transfusions in primary cranial vault remodeling: the role of aminocaproic acid.
Buchman, SR; Kapurch, J; Levi, B; Muraszko, KM; Oppenheimer, AJ; Ranganathan, K; Strahle, JM, 2014
)
1.36
"ε-Aminocaproic acid (EACA) has been used to reduce the rate of cerebral aneurysm rerupture before definitive treatment. "( ε-Aminocaproic acid in angiographically negative subarachnoid hemorrhage patients is safe: a retrospective review of 83 consecutive patients.
Barrow, DL; Cawley, CM; Hui, FK; Lieber, M; Moskowitz, SI; Schuette, AJ; Spiotta, AM, 2012
)
1.82

Treatment

Aminocaproic acid treated femur fractures healed with a significantly smaller cartilaginous callus. This effect was also observed in the ectopic transplantation assays.

ExcerptReferenceRelevance
"Aminocaproic acid treated femur fractures healed with a significantly smaller cartilaginous callus, and this effect was also observed in the ectopic transplantation assays. "( Temporary inhibition of the plasminogen activator inhibits periosteal chondrogenesis and promotes periosteal osteogenesis during appendicular bone fracture healing.
Bradaschia-Correa, V; Bravo, D; Coughlin, T; Huo, J; Josephson, AM; Lee, SN; Leucht, P; Mizrahi, MM; Neibart, SS; Wong, MZ; Yim, NL, 2018
)
1.92
"ε-Aminocaproic acid treatment was initiated and was associated with rapid clinical improvement and diminished fibrinolysis based on a modified plasma-based thromboelastogram."( Thromboelastographic evidence of inhibition of fibrinolysis after ε-aminocaproic acid administration in a dog with suspected acute traumatic coagulopathy.
Olver, CS; Sullivan, LA; Venn, E; Yoo, SH, 2016
)
1.23

Toxicity

epsilon-aminocaproic acid was found to be effective and safe for treatment of hyperfibrinolysis in patients with cirrhosis. intravenous aminocapproic acid is effective andsafe in total knee and hip arthroplasty without increasing the incidence of thromboembolic events.

ExcerptReferenceRelevance
" The LD50 tests were made in rats and mice using both compounds."( Antitumor effect and toxicity of two new active-site-directed irreversible ornithine decarboxylase and extrahepatic arginase inhibitors.
Joseph-Nathan, P; Koizumi, G; Muñoz, O; Trujillo-Ferrara, J; Yañez, R, 1992
)
0.28
"The pharmacologic management of hemostasis in patients undergoing cardiopulmonary bypass may be accompanied by adverse responses."( Hemostatic agents and their safety.
Levy, JH, 1999
)
0.3
" Levels of S-100beta and neuron-specific enolase were similar with both therapies, confirming that there was no difference in the occurrence of any adverse neurologic events in either group."( Comparison of epsilon aminocaproic acid and low-dose aprotinin in cardiopulmonary bypass: efficiency, safety and cost.
O'Brien, MF; Ray, MJ, 2001
)
0.63
" In general, these alternatives are safe with proper dosing and monitoring of effects."( Safety and efficacy of methods for reducing perioperative allogeneic transfusion: a critical review of the literature.
Wells, PS,
)
0.13
"epsilon-aminocaproic acid was found to be effective and safe for treatment of hyperfibrinolysis in patients with cirrhosis."( The efficacy and safety of epsilon-aminocaproic acid treatment in patients with cirrhosis and hyperfibrinolysis.
Gunawan, B; Runyon, B, 2006
)
1.05
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32
" More active, stable and less toxic CPPs can be designed by optimizing the position and number of R, D-R, X and B residues."( Cell-penetrating peptides as transporters for morpholino oligomers: effects of amino acid composition on intracellular delivery and cytotoxicity.
Hassinger, JN; Iversen, PL; Lovejoy, CE; Moulton, HM; Nelson, MH; Wu, RP; Youngblood, DS, 2007
)
0.34
" The analysis of the clinical efficacy and safety of the agents was based on the following perioperative data: the incidence of adverse reactions and complications associated with the administration of the agents, the frequency and amount of transfused donor blood components, the volume of blood loss, and the rate of resternotomies."( [The efficacy and safety of tranexamic acid and epsilon-aminocapronic acid in cardiac surgery under extracorporeal circulation].
Buniatian, AA; Charnaia, MA; Gladysheva, VG; Iavorovskiĭ, AG; Morozov, IuA; Tolstova, IA; Ziuliaeva, TP,
)
0.13
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36
"Short-term (<72 hour) application of EACA does not result in an increase in adverse events in patients with ANSAH."( ε-Aminocaproic acid in angiographically negative subarachnoid hemorrhage patients is safe: a retrospective review of 83 consecutive patients.
Barrow, DL; Cawley, CM; Hui, FK; Lieber, M; Moskowitz, SI; Schuette, AJ; Spiotta, AM, 2012
)
1.1
"The evaluated wound dressing seems to be safe and effective in reducing time to hemostasis in large arterial access sites."( Hemostatic Wound Dressing for Postinterventional Hemostasis in Large Femoral Artery Access Sites: An Initial Efficacy and Safety Study.
Bley, TA; Dierks, A; Hassold, N; Kickuth, R; Sauer, A; Wolfschmidt, F, 2016
)
0.43
"The aim was to utilize the Pediatric Craniofacial Surgery Perioperative Registry database to identify the safety profile of antifibrinolytic therapy for cranial vault reconstructive surgery by reporting the incidence of adverse events as they relate to exposure to tranexamic acid and aminocaproic acid compared to no exposure to antifibrinolytics."( Safety of antifibrinolytics in cranial vault reconstructive surgery: a report from the pediatric craniofacial collaborative group.
Cladis, FP; Fernandez, AM; Glover, CD; Goobie, SM; Huang, H; Reddy, SK; Stricker, PA; Zurakowski, D, 2017
)
0.63
" The outcomes evaluated included any perioperative neurological adverse event including seizures or seizure-like movements and thromboembolic events."( Safety of antifibrinolytics in cranial vault reconstructive surgery: a report from the pediatric craniofacial collaborative group.
Cladis, FP; Fernandez, AM; Glover, CD; Goobie, SM; Huang, H; Reddy, SK; Stricker, PA; Zurakowski, D, 2017
)
0.46
" Secondary outcomes were other adverse events, blood transfusion, and blood loss."( The Safety and Efficacy of Lysine Analogues in Cancer Patients: A Systematic Review and Meta-Analysis.
Breau, RH; Cagiannos, I; Cnossen, S; Fergusson, DA; Fergusson, NA; Hutton, B; Lavallée, LT; Montroy, J; Morash, C, 2017
)
0.46
"In summary, these data suggest that administration of εACA is a safe adjuvant therapy in the management of cranial dAVFs and CCFs that are incompletely treated endovascularly."( Incompletely obliterated cranial arteriovenous fistulae are safely and effectively treated with adjuvant ε-aminocaproic acid.
Cawley, CM; Dion, JE; Grossberg, JA; Howard, BM; Prater, A; Tong, FC, 2018
)
0.69
"Based on the present meta-analysis, intravenous aminocaproic acid is effective and safe in total knee and hip arthroplasty without increasing the incidence of thromboembolic events."( The effectiveness and safety of aminocaproic acid for reducing blood loss in total knee and hip arthroplasty: A meta-analysis.
Dong, Q; Hu, F; Sun, X; Zhang, Y, 2018
)
1.02
"This meta-analysis demonstrated that EACA could be safe and potentially efficacious for reducing blood loss and transfusions volume in patients with spinal deformity surgeries when compared with placebo."( The Efficacy and Safety of Epsilon-Aminocaproic Acid for Blood Loss and Transfusions in Spinal Deformity Surgery: A Meta-Analysis.
Chen, R; Gong, M; Xiang, Z, 2019
)
0.79
" Few studies found adverse events, and no difference in incidence or type of adverse events was seen between the antifibrinolytic and the placebo group."( Efficacy and Safety of Antifibrinolytic Drugs in Pediatric Surgery: A Systematic Review.
Fenger-Eriksen, C; Hansen, AK; Hovgesen, NT; Hvas, AM; Larsen, JB, 2021
)
0.62
" However, more large-scale trials are needed to examine the long-term adverse side effects of EACA in spinal fusion surgery."( The Efficacy and Safety of Epsilon-Aminocaproic Acid for Perioperative Blood Management in Spinal Fusion Surgery: A Systematic Review and Meta-Analysis.
Cen, Y; Li, S; Xing, F; Zhang, Z, 2021
)
0.9

Pharmacokinetics

Pharmacokinetic modeling of epsilon-aminocaproic acid in children undergoing cardiac surgery suggests that there are developmental differences in pharmacokinetic variables. There are no population-specific pharmacokinetics data to guide dosing.

ExcerptReferenceRelevance
"In rabbits and rats pharmacokinetic studies on the anti-fibrinolytics 4-aminomethylbenzoic acid (PAMBA), trans-4-aminomethylcyclohexane-1-carboxylic acid (AMCA), and epsilon-aminocaproic acid (EACA) were carried out using the tritium labelled compounds."( [Pharmacokinetic studies with 3H-labelled synthetic antifibrinolytics].
Klöcking, HP; Markwardt, F; Richter, M, 1982
)
0.46
" The authors developed a pharmacokinetic model for EACA elimination in surgical patients, tested whether adjustments for cardiopulmonary bypass (CPB) would improve the model, and then used the model to develop an EACA dosing schedule that would yield nearly constant EACA blood concentrations."( Pharmacokinetics of epsilon-aminocaproic acid in patients undergoing aortocoronary bypass surgery.
Butterworth, J; Hudspeth, AS; James, RL; Lin, Y; Prielipp, RC, 1999
)
0.6
" Blood concentrations of EACA, measured by high-performance liquid chromatography, were subjected to mixed-effects pharmacokinetic modeling."( Pharmacokinetics of epsilon-aminocaproic acid in patients undergoing aortocoronary bypass surgery.
Butterworth, J; Hudspeth, AS; James, RL; Lin, Y; Prielipp, RC, 1999
)
0.6
" We hypothesized that children would have different pharmacokinetic variables and require a dosing scheme different from adults to maintain stable and effective serum epsilonACA concentrations."( The pharmacokinetics of epsilon-aminocaproic acid in children undergoing surgical repair of congenital heart defects.
Barclay, D; Bennett, J; Butterworth, JF; Hines, MH; James, RL; Lin, YA; O'Brien, JJ; Ririe, DG, 2002
)
0.6
"Pharmacokinetic modeling of epsilon-aminocaproic acid in children undergoing cardiac surgery suggests that there are developmental differences in pharmacokinetic variables."( The pharmacokinetics of epsilon-aminocaproic acid in children undergoing surgical repair of congenital heart defects.
Barclay, D; Bennett, J; Butterworth, JF; Hines, MH; James, RL; Lin, YA; O'Brien, JJ; Ririe, DG, 2002
)
0.87
" Plasma concentration versus time data were evaluated by use of a pharmacokinetic analysis computer program."( Pharmacokinetics and pharmacodynamics of epsilon-aminocaproic acid in horses.
Dallap, BL; Dolente, BA; Ross, J; Sweeney, RW, 2007
)
0.59
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
" Thus, pharmacokinetic changes in rats with acute renal failure induced by uranyl nitrate (U-ARF rats) were investigated in this study."( Reduced clearance of ε-acetamidocaproic acid in rats with acute renal failure induced by uranyl nitrate.
Choi, YH; Han, SY; Lee, MG; Yang, SH; Yoon, I, 2012
)
0.38
"Despite demonstrated efficacy of ϵ-aminocaproic acid (EACA) in reducing blood loss in adolescents undergoing spinal fusion, there are no population-specific pharmacokinetic data to guide dosing."( Population pharmacokinetics of ϵ-aminocaproic acid in adolescents undergoing posterior spinal fusion surgery.
Fiadjoe, JE; Gastonguay, MR; Goebel, TK; Pruitt, EY; Singh, D; Stricker, PA; Sussman, EM; Zuppa, AF, 2015
)
0.98
"Population pharmacokinetic parameters were estimated using a two-compartment disposition model with allometrically scaled weight and an age effect on clearance."( Population pharmacokinetics of ϵ-aminocaproic acid in adolescents undergoing posterior spinal fusion surgery.
Fiadjoe, JE; Gastonguay, MR; Goebel, TK; Pruitt, EY; Singh, D; Stricker, PA; Sussman, EM; Zuppa, AF, 2015
)
0.7
" Dosing schemes for neonates are often based on adult regimens, or are simply empiric, in part due to the lack of neonatal pharmacokinetic information."( Pharmacokinetics of ε-Aminocaproic Acid in Neonates Undergoing Cardiac Surgery with Cardiopulmonary Bypass.
Alfieris, GM; Anderson, B; Angona, RE; Cholette, JM; Eaton, MP; Sweeney, DM; Venuto, C, 2015
)
0.73
" The pharmacokinetics of ACA in serum were best described by a three-compartment model with a terminal elimination half-life of 24."( Pharmacokinetics of aminocaproic acid in thoroughbred horses.
Cole, C; Hay, S; Maxwell, L; McCarrel, TM, 2023
)
1.23

Bioavailability

ExcerptReferenceRelevance
" The bioavailability was about 52."( [Absorption, tissue distribution, and excretion of zinc acexamate in rats].
Liu, ZF; Song, LS; Wang, MW; Wu, JF, 1996
)
0.29
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Epsilon-aminocaproic acid (EACA) is commonly infused during cardiac surgery using empiric dosing schemes. HemoSTATUS clot ratio values and heparin dose response values are not significantly affected after IV dosing of EACA.

ExcerptRelevanceReference
" The last 20 patients of the present series have been treated with very low doses of AMCA associated with parotid kallikrein inhibitor (Trasylol); this dosage has been effective in preventing recurrence and has appeared to be freer from severe side effects."( The use of antifibrinolytic drugs in aneurysmal subarachnoid hemorrhage.
Schisano, G, 1978
)
0.26
" Partial correction of hyperfibrinolysis, attained by adequate dosage of antifibrinolytic drugs and administered under the control of the proposed diagnostic method, makes possible to attain normalization of haemostatic processes in the operation wound and to avoid intensification of the syndrome of disseminated intravascular coagulation of blood."( Hyperfibrinolysis: its express diagnosis and role in the development of haemorrhagic syndrome after cardiopulmonary bypass.
Bauman, NN; Levit, AL; Sukhanov, VA, 1988
)
0.27
" Twenty-six took an oral dosage of 50 mg/kg ("half dose") every four hours for five days, up to a maximum of 30 g/day, and 33 patients received 100 mg/kg ("full-dose") every four hours up to a maximum of 30 g/day."( A comparison of two dose regimens of epsilon aminocaproic acid in the prevention and management of secondary traumatic hyphemas.
Anderson, RJ; Fiscella, R; Frenkel, M; Goldberg, MF; Palmer, DJ, 1986
)
0.53
" Thrombin, at a dosage producing a fibrinogen consumption of 70% within 4 h (1 unit/kg/min), failed to produce extrapulmonary microthrombi unless fibrinolysis inhibition (epsilon-aminocaproic acid-EACA) or alpha-adrenergic stimulation (norepinephrine) were provided simultaneously."( Vasoactive agents and production of thrombosis during intravascular coagulation 1--comparative effects of norepinephrine in thrombin and adenosine diphosphate (ADP) treated rabbits.
Daoust-Fiorilli, J; Latour, JG; Léger-Gauthier, C, 1984
)
0.46
" In summary, considering the results obtained in the cases above, we believe that due to its good tolerance and moderate cost, epsilon-amino-caproic acid at the abovementioned dosage is an excellent pharmacological agent in the treatment of Osler's hereditary angioneurotic edema."( Epsilon-amino-caproic acid in the treatment of Osler's hereditary angioneurotic edema.
Diéguez, I; Fernández, M; Neffen, H; Oehling, A,
)
0.13
" Time-response and dose-response studies of the resultant plasma levels of fibrinolytic activity were measured by a modification of a standard fibrin plate technique."( Measurement of fibrinolytic activity after epsilon-aminocaproic acid administration in rats (Rattus norvegicus).
Barry, KJ; Gogjian, MA; Stein, BM, 1981
)
0.51
" Apart from determination of titre by indirect ELISA, dose-response behaviour and specificity of these antisera were also compared."( Antibody to folic acid: increased specificity and sensitivity in ELISA by using epsilon-aminocaproic acid modified BSA as the carrier protein.
Ali, E; Das Sarma, J; Dhar, TK; Duttagupta, C, 1995
)
0.51
"7% of the administered dosage in feces within 48 h period, and the excreted amount from urine and bile was very small."( [Pharmacokinetics of zinc acexamate (ZAC) in rats].
Ji, XJ; Li, HY; Liu, XM, 1995
)
0.29
" On the other hand, AIHA did not affect the total length of oestrous cycle at the same dosage level used to interrupt pregnancy."( Antifertility effects of (+)-S-2-amino-6-iodoacetamidohexanoic acid (2-AIHA) in female rats.
Ceballos, G; Chamorro, G; Munoz, O; Salazar, M; Salazar, S; Trujillo, J; Yanez, R, 1996
)
0.29
" The initial dosage was 4 g po q6h."( Rhabdomyolysis induced by epsilon-aminocaproic acid.
Rubinger, M; Seymour, BD, 1997
)
0.58
" In conclusion, a dosage of 600 mg/d of ACZ has shown to be as effective as 40 mg/d of FMT in the healing of duodenal ulcer."( [A multicenter clinical trial. Zinc acexamate versus famotidine in the treatment of acute duodenal ulcer. Study Group of Zinc acexamate (new UP doses)].
Arenas, JI; Belda, O; de la Santa, Jw; Diago, A; Domínguez, A; Fernández, C; García-Plaza, A; Martín, L; Pallarés, A; Rodrigo, L, 1996
)
0.29
" Although plasma EACA concentrations greater than 130 microg/mL were consistently achieved, we observed a marked variability (more than sixfold) in plasma concentrations and bleeding outcomes despite the use of a weight-based dosing regimen."( epsilon-Aminocaproic acid plasma levels during cardiopulmonary bypass.
Ayuso, L; Bennett-Guerrero, E; Canada, AT; Mythen, MG; Newman, MF; Reves, JG; Sorohan, JG, 1997
)
0.73
" This is followed by a comparison of the efficacy of each intervention and any dose-response relationship."( Aprotinin versus lysine analogues: the debate continues.
Royston, D, 1998
)
0.3
"Epsilon-aminocaproic acid (EACA) is commonly infused during cardiac surgery using empiric dosing schemes."( Pharmacokinetics of epsilon-aminocaproic acid in patients undergoing aortocoronary bypass surgery.
Butterworth, J; Hudspeth, AS; James, RL; Lin, Y; Prielipp, RC, 1999
)
1.03
" Our data indicate that HemoSTATUS clot ratio values and heparin dose response values are not significantly affected after IV dosing of epsilon-aminocaproic acid."( The effect of epsilon-aminocaproic acid on HemoSTATUS and kaolin-activated clotting time measurements.
Bigham, M; Despotis, GJ; Saleem, R; Spitznagel, E, 2000
)
0.82
" We also review applications of antifibrinolytic agents to neurovascular disorders and discuss the mechanism of action, dosing strategy, contraindications, and possible complications associated with the use of EACA."( Adjuvant use of epsilon-aminocaproic acid (Amicar) in the endovascular treatment of cranial arteriovenous fistulae.
Cloft, HJ; Dion, JE; Do, HM; Jensen, ME; Kallmes, DF; Lanzino, G; Marx, WF; West, K, 2000
)
0.61
" This retrospective study suggests that moderate epsilon-aminocaproic acid dosing during cardiac surgery is safe for the kidney; however, this inference is based on a single marker of renal dysfunction and requires prospective confirmation using a variety of tests of renal function."( The association of epsilon-aminocaproic acid with postoperative decrease in creatinine clearance in 1502 coronary bypass patients.
Black, J; Newman, MF; Phillips-Bute, B; Reddan, DN; Stafford-Smith, M, 2000
)
0.85
" We hypothesized that epsilon-ACA concentrations using this dosing scheme would differ by gender because of differences in body composition and weight-adjusted volumes of distribution."( Gender does not influence epsilon-aminocaproic acid concentrations in adults undergoing cardiopulmonary bypass.
Bennett, J; Butterworth, J; James, RL; Lin, YA; Prielipp, RC, 2001
)
0.59
"epsilon-Aminocaproic acid (epsilonACA) is often administered to children undergoing cardiac surgery by using empiric dosing techniques."( The pharmacokinetics of epsilon-aminocaproic acid in children undergoing surgical repair of congenital heart defects.
Barclay, D; Bennett, J; Butterworth, JF; Hines, MH; James, RL; Lin, YA; O'Brien, JJ; Ririe, DG, 2002
)
1.03
" Based on these data, a dosing modification in children is suggested which may better maintain serum concentrations in children when compared with adults."( The pharmacokinetics of epsilon-aminocaproic acid in children undergoing surgical repair of congenital heart defects.
Barclay, D; Bennett, J; Butterworth, JF; Hines, MH; James, RL; Lin, YA; O'Brien, JJ; Ririe, DG, 2002
)
0.6
" In general, these alternatives are safe with proper dosing and monitoring of effects."( Safety and efficacy of methods for reducing perioperative allogeneic transfusion: a critical review of the literature.
Wells, PS,
)
0.13
"Sixty patients were randomized in a double-blind fashion to receive epsilon-aminocaproic acid, aprotinin, or saline (placebo) in similar dosing regimens (loading dose, pump prime, and infusion)."( Antifibrinolytic therapy during cardiopulmonary bypass reduces proinflammatory cytokine levels: a randomized, double-blind, placebo-controlled study of epsilon-aminocaproic acid and aprotinin.
Brouse, CF; Chi, L; Dimaio, JM; Greilich, PE; Jessen, ME; Whitten, CW, 2003
)
0.75
"When dosed in a similar manner, epsilon-aminocaproic acid seems to be as effective as aprotinin at reducing interleukin-6 and interleukin-8 levels in patients undergoing primary coronary artery bypass graft surgery."( Antifibrinolytic therapy during cardiopulmonary bypass reduces proinflammatory cytokine levels: a randomized, double-blind, placebo-controlled study of epsilon-aminocaproic acid and aprotinin.
Brouse, CF; Chi, L; Dimaio, JM; Greilich, PE; Jessen, ME; Whitten, CW, 2003
)
0.78
" Symptoms like mild nausea and vertigo were seen as the side-effects of this medicine when high intravenous dosage was administered."( Role of epsilon amino caproic acid in the management of haemophilic patients with inhibitors.
Ghosh, K; Jijina, F; Mohanty, D; Shetty, S, 2004
)
0.32
" Then the different dosage BCG with or without antifibrinolytic agents was regular instilled into bladders (once a week, then once a month after 6 times)."( [Clinical investigation on the effect of intravesical instillation of antifibrinolytic agents with bacillus Calmette-Guerin on preventing bladder cancer recurrence].
Chen, J; Ding, GQ; Jin, XD; Lu, J; Shen, ZJ; Shi, SF, 2005
)
0.33
" Even if the dosage of BCG was reduced by half, the efficacy didn't changed."( [Clinical investigation on the effect of intravesical instillation of antifibrinolytic agents with bacillus Calmette-Guerin on preventing bladder cancer recurrence].
Chen, J; Ding, GQ; Jin, XD; Lu, J; Shen, ZJ; Shi, SF, 2005
)
0.33
" This data help correct dosing of antifibrinolytics to patients with hyperfibrinolysis."( In vitro simulation of thrombolysis inhibition.
Stief, TW, 2008
)
0.35
" However, these studies have been criticized for including multiple centers and different dosing strategies."( Impact of aprotinin on adverse clinical outcomes and mortality up to 12 years in a registry of 3,337 patients.
Lee, PH; Murphy, SA; Olenchock, SA; Symes, J; Tolis, G; Yehoshua, T, 2008
)
0.35
" We undertook this study to test the hypothesis that EACA, when dosed appropriately, is not inferior to aprotinin at reducing fibrinolysis and blood loss."( The effect of epsilon-aminocaproic acid and aprotinin on fibrinolysis and blood loss in patients undergoing primary, isolated coronary artery bypass surgery: a randomized, double-blind, placebo-controlled, noninferiority trial.
Beckham, JM; Butterworth, JF; Greilich, PE; Jessen, ME; Nuttall, GA; Satyanarayana, N; Wall, MH; Whitten, CW, 2009
)
0.67
"When dosed in a pharmacologically guided manner, EACA is not inferior to aprotinin in reducing fibrinolysis and blood loss in patients undergoing primary, isolated coronary artery bypass surgery."( The effect of epsilon-aminocaproic acid and aprotinin on fibrinolysis and blood loss in patients undergoing primary, isolated coronary artery bypass surgery: a randomized, double-blind, placebo-controlled, noninferiority trial.
Beckham, JM; Butterworth, JF; Greilich, PE; Jessen, ME; Nuttall, GA; Satyanarayana, N; Wall, MH; Whitten, CW, 2009
)
0.67
" The therapeutic plasma concentration of EACA has been scientifically determined for the adult population, but the current recommended dosage for neonates has been empirically derived from adult studies."( The effective concentration of epsilon-aminocaproic Acid for inhibition of fibrinolysis in neonatal plasma in vitro.
Eaton, MP; Liu, X; Tu, X; Wissler, RN; Yurka, HG; Zanghi, CN, 2010
)
0.63
" This concentration is significantly less than that targeted by current dosing schemes, indicating that neonates are possibly being exposed to greater levels of EACA than is clinically necessary."( The effective concentration of epsilon-aminocaproic Acid for inhibition of fibrinolysis in neonatal plasma in vitro.
Eaton, MP; Liu, X; Tu, X; Wissler, RN; Yurka, HG; Zanghi, CN, 2010
)
0.63
" Demographic information, medical and surgical histories, and epsilon aminocaproic acid dosing and outcomes were recorded."( Preliminary experience with epsilon aminocaproic acid for treatment of intractable upper tract hematuria in children with hematological disorders.
Cerwinka, WH; Elmore, JM; Kaye, JD; Kirsch, AJ; Smith, EA, 2010
)
0.87
" Analysis of data is complicated as the dosing scheme, especially for tranexamic acid, varies extremely and the agents are highly overdosed in most relevant trials."( Re-evaluation of the role of antifibrinolytic therapy with lysine analogs during cardiac surgery in the post aprotinin era.
Koster, A; Schirmer, U, 2011
)
0.37
" Although TXA is a long known drug available on the market for more than 50 years, the studies connecting factors of indication, dosage regimen and safety are limited especially in children and infants."( [Hemostasis and antifibrinolytic therapy in major pediatric surgery].
Hertfelder, HJ; Schindler, E, 2013
)
0.39
" Although horses are hypofibrinolytic compared to humans, dosing schemes have been derived from pharmacokinetic studies targeting plasma concentrations in humans."( Therapeutic plasma concentrations of epsilon aminocaproic acid and tranexamic acid in horses.
Brainard, BM; Divers, T; Epstein, K; Fletcher, DJ; Radcliffe, R,
)
0.39
"Current dosing schemes for EACA and TEA in horses may be as much as 20× higher than necessary, potentially increasing cost of treatment and risk of adverse effects."( Therapeutic plasma concentrations of epsilon aminocaproic acid and tranexamic acid in horses.
Brainard, BM; Divers, T; Epstein, K; Fletcher, DJ; Radcliffe, R,
)
0.39
"44 μM, no detectable activity against GABAa, and with DMPK properties leading to a predicted dose of 340 mg twice a day oral dosing in humans."( Discovery of the Fibrinolysis Inhibitor AZD6564, Acting via Interference of a Protein-Protein Interaction.
Boström, J; Cheng, L; Evertsson, E; Fex, T; Gustafsson, D; Hilgendorf, C; Jonforsen, M; Karle, M; Larsson, LO; Lindberg, W; Ohlsson, B; Pahlén, S; Pettersen, D; Plowright, AT; Schell, P; Thelin, A; Wahlund, G; Xue, Y, 2014
)
0.4
" In the steroids and ACA cohort (n=82), there were no significant differences in 30, 60, 100, day, ICU and hospital mortality between the dosing groups."( Low-, medium- and high-dose steroids with or without aminocaproic acid in adult hematopoietic SCT patients with diffuse alveolar hemorrhage.
Dinh, A; Dong, W; Ensor, J; Feng, L; Haque, SA; Nates, JL; Popat, U; Price, KJ; Rathi, NK; Rondon, G; Tanner, AR; Wallace, SK, 2015
)
0.67
" The aim of this study was to determine the pharmacokinetics of EACA in adolescents undergoing spinal fusion surgery and make dosing recommendations."( Population pharmacokinetics of ϵ-aminocaproic acid in adolescents undergoing posterior spinal fusion surgery.
Fiadjoe, JE; Gastonguay, MR; Goebel, TK; Pruitt, EY; Singh, D; Stricker, PA; Sussman, EM; Zuppa, AF, 2015
)
0.7
" Previously reported data from infants undergoing craniofacial surgery were included in the model to enable dosing recommendations over a wide range of weights, ages, and diagnoses."( Population pharmacokinetics of ϵ-aminocaproic acid in adolescents undergoing posterior spinal fusion surgery.
Fiadjoe, JE; Gastonguay, MR; Goebel, TK; Pruitt, EY; Singh, D; Stricker, PA; Sussman, EM; Zuppa, AF, 2015
)
0.7
"The following dosing schemes are recommended according to patient weight: weight <25 kg, 100 mg kg(-1) loading dose and 40 mg kg(-1) h(-1) infusion; weight ≤25 kg-<50 kg, 100 mg kg(-1) loading dose and 35 mg kg(-1) h(-1) infusion; and weight ≥50 kg, 100 mg kg(-1) loading dose and 30 mg kg(-1) h(-1) infusion."( Population pharmacokinetics of ϵ-aminocaproic acid in adolescents undergoing posterior spinal fusion surgery.
Fiadjoe, JE; Gastonguay, MR; Goebel, TK; Pruitt, EY; Singh, D; Stricker, PA; Sussman, EM; Zuppa, AF, 2015
)
0.7
" Dosing schemes for neonates are often based on adult regimens, or are simply empiric, in part due to the lack of neonatal pharmacokinetic information."( Pharmacokinetics of ε-Aminocaproic Acid in Neonates Undergoing Cardiac Surgery with Cardiopulmonary Bypass.
Alfieris, GM; Anderson, B; Angona, RE; Cholette, JM; Eaton, MP; Sweeney, DM; Venuto, C, 2015
)
0.73
" Parameter estimates (standardized to a 70-kg person) were used to develop a dosing regimen intended to maintain a target concentration shown to inhibit fibrinolysis in neonatal plasma (50 mg/l)."( Pharmacokinetics of ε-Aminocaproic Acid in Neonates Undergoing Cardiac Surgery with Cardiopulmonary Bypass.
Alfieris, GM; Anderson, B; Angona, RE; Cholette, JM; Eaton, MP; Sweeney, DM; Venuto, C, 2015
)
0.73
" Simulation showed a dosing regimen with a loading dose of 40 mg/kg and an infusion of 30 mg · kg · h, with a pump prime concentration of 100 mg/l maintained plasma concentrations above 50 mg/l in 90% of neonates during cardiopulmonary bypass surgery."( Pharmacokinetics of ε-Aminocaproic Acid in Neonates Undergoing Cardiac Surgery with Cardiopulmonary Bypass.
Alfieris, GM; Anderson, B; Angona, RE; Cholette, JM; Eaton, MP; Sweeney, DM; Venuto, C, 2015
)
0.73
" The model formulations were representative for oral solutions (co-solvents), parenteral solutions (buffer species) and solid dosage forms (organic acids applicable for solubility enhancement)."( Evaluation of microwave oven heating for prediction of drug-excipient compatibilities and accelerated stability studies.
Cornett, C; Hansen, SH; Schou-Pedersen, AM; Østergaard, J, 2015
)
0.42
" Further studies are needed to clarify optimal therapeutic dosing and to identify mechanisms of neuroprotection in rat SBI models."( Epsilon Aminocaproic Acid Pretreatment Provides Neuroprotection Following Surgically Induced Brain Injury in a Rat Model.
Applegate, RL; Khatibi, N; Komanapalli, ES; Martin, RD; Rolland, W; Sherchan, P; Tang, J; Zhang, JH, 2016
)
0.87
" Its use in zoological medicine is rare, and dosage is anecdotal."( PHARMACOKINETIC STUDY OF ORAL ε-AMINOCAPROIC ACID IN THE NORTHERN ELEPHANT SEAL (MIROUNGA ANGUSTIROSTRIS).
Abou-Madi, N; Arnold, RD; Davis, JT; Fletcher, DJ; Gulland, F; Johnson, S; Kaye, S; Nie, B, 2016
)
0.72
" Current dosing recommendations are derived from adult extrapolations, and may or may not have clinical relevance."( Blood loss and transfusion requirements with epsilon-aminocaproic acid use during cranial vault reconstruction surgery.
Demke, J; Nagy, L; Saadeh, C; Thompson, ME; Watkins, P, 2017
)
0.7
"Using a standardized dosing regimen of EACA during craniosynostosis surgery, we found statistical significance in blood loss and transfusion requirements in surgeries of the shortest duration."( Blood loss and transfusion requirements with epsilon-aminocaproic acid use during cranial vault reconstruction surgery.
Demke, J; Nagy, L; Saadeh, C; Thompson, ME; Watkins, P, 2017
)
0.7
" Antifibrinolytic dosage regimes should be based on pharmacokinetic data avoiding high doses."( Safety of antifibrinolytics in cranial vault reconstructive surgery: a report from the pediatric craniofacial collaborative group.
Cladis, FP; Fernandez, AM; Glover, CD; Goobie, SM; Huang, H; Reddy, SK; Stricker, PA; Zurakowski, D, 2017
)
0.46
"The purpose of this study was to determine if a higher dosing of ε-aminocaproic acid (EACA) is associated with less perioperative blood loss than a lower dose."( Unexpected higher blood loss associated with higher dose ε-aminocaproic acid in pediatric scoliosis surgery.
Austin, T; Lam, H; Martus, J; Nguyen, T; Schoenecker, J, 2019
)
0.99
"Antifibrinolytic drugs are used to reduce blood loss and subsequent transfusions during surgery and following trauma, but the optimal dosing regimen in the pediatric population is still unresolved."( Efficacy and Safety of Antifibrinolytic Drugs in Pediatric Surgery: A Systematic Review.
Fenger-Eriksen, C; Hansen, AK; Hovgesen, NT; Hvas, AM; Larsen, JB, 2021
)
0.62
" Antifibrinolytic drugs are part of a multifaceted approach aimed at reducing bleeding, though sufficiently sized pediatric studies are sparse, and dosing algorithms are heterogeneous."( Antifibrinolytic Drugs for the Prevention of Bleeding in Pediatric Cardiac Surgery on Cardiopulmonary Bypass: A Systematic Review and Meta-analysis.
Hunt, BJ; Murdoch, IA; Sangaran, DP; Siemens, K; Tibby, SM, 2022
)
0.72
" Different dosing regimens were compared."( Antifibrinolytic Drugs for the Prevention of Bleeding in Pediatric Cardiac Surgery on Cardiopulmonary Bypass: A Systematic Review and Meta-analysis.
Hunt, BJ; Murdoch, IA; Sangaran, DP; Siemens, K; Tibby, SM, 2022
)
0.72
" There was no clear dose-response effect for TXA nor aprotinin."( Antifibrinolytic Drugs for the Prevention of Bleeding in Pediatric Cardiac Surgery on Cardiopulmonary Bypass: A Systematic Review and Meta-analysis.
Hunt, BJ; Murdoch, IA; Sangaran, DP; Siemens, K; Tibby, SM, 2022
)
0.72
" As sufficient data are lacking, large comparative trials are warranted to assess the relative safety and appropriate dosing regimens in pediatrics."( Antifibrinolytic Drugs for the Prevention of Bleeding in Pediatric Cardiac Surgery on Cardiopulmonary Bypass: A Systematic Review and Meta-analysis.
Hunt, BJ; Murdoch, IA; Sangaran, DP; Siemens, K; Tibby, SM, 2022
)
0.72
" This approach was effectively employed to evaluate the content of 6-aminocaproic acid in laboratory prepared dosage form with average percentage recovery of 100."( Benzofurazan -based fluorophore for the spectrofluorimetric determination of 6-Aminocaproic acid: Application to spiked human plasma and urine.
Anwer, EF; Derayea, SM; Nour El-Deen, DAM; Omar, MA, 2022
)
1.18
" Weight-based TXA dosing regimens have been compared to fixed-dose regimens of EACA with variable outcomes in perioperative blood product transfusions and chest tube output."( Comparison of trauma-dosed tranexamic acid versus aminocaproic acid in cardiac surgery in the setting of drug shortage.
Cook, BM; Dannemiller, RE; Goodberlet, MZ; Kelly, JM; Knowles, DM; Malloy, R, 2022
)
0.97
" We recommend following pharmacokinetic-based dosing guidelines for administration."( Safety of antifibrinolytics in 6583 pediatric patients having craniosynostosis surgery: A decade of data reported from the multicenter Pediatric Craniofacial Collaborative Group.
Benzon, HA; Goobie, SM; King, MR; Nelson, O; Pérez-Pradilla, C; Staffa, SJ; Stricker, PA, 2022
)
0.72
" Therefore, the discovery of novel antifibrinolytics with a higher specificity and lower dosage could vastly improve the applicability of these drugs."( 1,2,3-Triazole Derivatives as Novel Antifibrinolytic Drugs.
Balcells, M; Biarnés, X; Bosch-Sanz, O; Caveda, L; Martorell, J; Pedreño, J; Rabadà, Y; Sánchez-García, D, 2022
)
0.72
" Further studies are needed to adjust dosage of EACA to make better comparison of the two drugs."( Combination of Intravenous and Intra-Articular Application of Tranexamic Acid and Epsilon-Aminocaproic Acid in Primary Total Knee Arthroplasty: A Prospective Randomized Controlled Trial.
Li, M; Liu, Y; Ma, J; Shen, B; Si, H; Xu, J; Zheng, C, 2023
)
1.13
" In six of the eight horses, ACA was above the LLOQ 168 h after dosing in serum and urine samples."( Pharmacokinetics of aminocaproic acid in thoroughbred horses.
Cole, C; Hay, S; Maxwell, L; McCarrel, TM, 2023
)
1.23
" This study aimed to evaluate the indications for the use of TXA and EACA in cats and to describe dosing regimens used, occurrence of adverse events, and patient outcomes."( Evaluation of Therapeutic Use of Antifibrinolytics in Cats.
Barfield, D; Cutler, S; Manson, KC; Stanzani, G; Thomas, EK; Wahldén, L; Wilson, HE, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
antifibrinolytic drugA drug that prevent fibrinolysis or lysis of a blood clot or thrombus.
hematologic agentDrug that acts on blood and blood-forming organs and those that affect the hemostatic system.
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
amino acid zwitterionThe zwitterionic form of an amino acid having a negatively charged carboxyl group and a positively charged amino group.
epsilon-amino acidAn amino acid in which the amino group is located on the carbon atom at the position epsilon to the carboxy group.
omega-amino fatty acidAny fatty acid n atoms long having an amino substituent at position n (omega).
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (26)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency2.23870.003245.467312,589.2998AID2517
Chain A, ATP-DEPENDENT DNA HELICASE Q1Homo sapiens (human)Potency6.30960.125919.1169125.8920AID2353
Chain A, Ferritin light chainEquus caballus (horse)Potency44.66845.623417.292931.6228AID2323
15-lipoxygenase, partialHomo sapiens (human)Potency0.00500.012610.691788.5700AID887
ATAD5 protein, partialHomo sapiens (human)Potency2.59180.004110.890331.5287AID493107
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency19.95260.011212.4002100.0000AID1030
regulator of G-protein signaling 4Homo sapiens (human)Potency0.42240.531815.435837.6858AID504845
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency0.13800.01237.983543.2770AID1645841
EWS/FLI fusion proteinHomo sapiens (human)Potency18.18100.001310.157742.8575AID1259252; AID1259253; AID1259256
nonstructural protein 1Influenza A virus (A/WSN/1933(H1N1))Potency10.00000.28189.721235.4813AID2326
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency5.74130.000214.376460.0339AID720692
arylsulfatase AHomo sapiens (human)Potency0.33811.069113.955137.9330AID720538
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency2.09760.035520.977089.1251AID504332
D(1A) dopamine receptorHomo sapiens (human)Potency0.12990.02245.944922.3872AID488982
chromobox protein homolog 1Homo sapiens (human)Potency94.56250.006026.168889.1251AID488953; AID540317
thyroid hormone receptor beta isoform aHomo sapiens (human)Potency0.39810.010039.53711,122.0200AID1479
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1Homo sapiens (human)Potency19.01150.425612.059128.1838AID504536
gemininHomo sapiens (human)Potency0.20600.004611.374133.4983AID624297
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency39.81070.251215.843239.8107AID504327
lamin isoform A-delta10Homo sapiens (human)Potency1.25890.891312.067628.1838AID1487
Rap guanine nucleotide exchange factor 3Homo sapiens (human)Potency125.89206.309660.2008112.2020AID720707
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
PlasminogenHomo sapiens (human)IC50 (µMol)105.00000.02503.628010.0000AID1154948
PlasminogenHomo sapiens (human)Ki53,000.00000.01701.15604.4000AID1558619
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, PLASMINOGENHomo sapiens (human)Kd11.00001.00006.000011.0000AID977611
Chain A, PLASMINOGENHomo sapiens (human)Kd11.00001.00006.000011.0000AID977611
Chain A, ApolipoproteinHomo sapiens (human)Kd20.000020.000020.000020.0000AID977611
PlasminogenHomo sapiens (human)Kd9.00001.10003.35009.0000AID1558612
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (49)

Processvia Protein(s)Taxonomy
angiogenesisRap guanine nucleotide exchange factor 3Homo sapiens (human)
adaptive immune responseRap guanine nucleotide exchange factor 3Homo sapiens (human)
signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayRap guanine nucleotide exchange factor 3Homo sapiens (human)
associative learningRap guanine nucleotide exchange factor 3Homo sapiens (human)
Rap protein signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
regulation of actin cytoskeleton organizationRap guanine nucleotide exchange factor 3Homo sapiens (human)
negative regulation of syncytium formation by plasma membrane fusionRap guanine nucleotide exchange factor 3Homo sapiens (human)
intracellular signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of GTPase activityRap guanine nucleotide exchange factor 3Homo sapiens (human)
regulation of angiogenesisRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of angiogenesisRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of protein export from nucleusRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of stress fiber assemblyRap guanine nucleotide exchange factor 3Homo sapiens (human)
regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of syncytium formation by plasma membrane fusionRap guanine nucleotide exchange factor 3Homo sapiens (human)
establishment of endothelial barrierRap guanine nucleotide exchange factor 3Homo sapiens (human)
cellular response to cAMPRap guanine nucleotide exchange factor 3Homo sapiens (human)
Ras protein signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
regulation of insulin secretionRap guanine nucleotide exchange factor 3Homo sapiens (human)
proteolysisPlasminogenHomo sapiens (human)
blood coagulationPlasminogenHomo sapiens (human)
negative regulation of cell population proliferationPlasminogenHomo sapiens (human)
negative regulation of cell-substrate adhesionPlasminogenHomo sapiens (human)
extracellular matrix disassemblyPlasminogenHomo sapiens (human)
tissue regenerationPlasminogenHomo sapiens (human)
fibrinolysisPlasminogenHomo sapiens (human)
positive regulation of blood vessel endothelial cell migrationPlasminogenHomo sapiens (human)
myoblast differentiationPlasminogenHomo sapiens (human)
muscle cell cellular homeostasisPlasminogenHomo sapiens (human)
tissue remodelingPlasminogenHomo sapiens (human)
biological process involved in interaction with symbiontPlasminogenHomo sapiens (human)
negative regulation of fibrinolysisPlasminogenHomo sapiens (human)
positive regulation of fibrinolysisPlasminogenHomo sapiens (human)
trophoblast giant cell differentiationPlasminogenHomo sapiens (human)
labyrinthine layer blood vessel developmentPlasminogenHomo sapiens (human)
mononuclear cell migrationPlasminogenHomo sapiens (human)
trans-synaptic signaling by BDNF, modulating synaptic transmissionPlasminogenHomo sapiens (human)
negative regulation of cell-cell adhesion mediated by cadherinPlasminogenHomo sapiens (human)
monoatomic ion transportProton-coupled amino acid transporter 1Homo sapiens (human)
amino acid transportProton-coupled amino acid transporter 1Homo sapiens (human)
taurine transmembrane transportProton-coupled amino acid transporter 1Homo sapiens (human)
proline transportProton-coupled amino acid transporter 1Homo sapiens (human)
alanine transportProton-coupled amino acid transporter 1Homo sapiens (human)
amino acid import across plasma membraneProton-coupled amino acid transporter 1Homo sapiens (human)
glycine transportProton-coupled amino acid transporter 1Homo sapiens (human)
proline transmembrane transportProton-coupled amino acid transporter 1Homo sapiens (human)
proton transmembrane transportProton-coupled amino acid transporter 1Homo sapiens (human)
L-alanine transportProton-coupled amino acid transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (22)

Processvia Protein(s)Taxonomy
guanyl-nucleotide exchange factor activityRap guanine nucleotide exchange factor 3Homo sapiens (human)
protein bindingRap guanine nucleotide exchange factor 3Homo sapiens (human)
protein domain specific bindingRap guanine nucleotide exchange factor 3Homo sapiens (human)
cAMP bindingRap guanine nucleotide exchange factor 3Homo sapiens (human)
protease bindingPlasminogenHomo sapiens (human)
endopeptidase activityPlasminogenHomo sapiens (human)
serine-type endopeptidase activityPlasminogenHomo sapiens (human)
signaling receptor bindingPlasminogenHomo sapiens (human)
protein bindingPlasminogenHomo sapiens (human)
serine-type peptidase activityPlasminogenHomo sapiens (human)
enzyme bindingPlasminogenHomo sapiens (human)
kinase bindingPlasminogenHomo sapiens (human)
protein domain specific bindingPlasminogenHomo sapiens (human)
apolipoprotein bindingPlasminogenHomo sapiens (human)
protein-folding chaperone bindingPlasminogenHomo sapiens (human)
protein antigen bindingPlasminogenHomo sapiens (human)
amino acid:proton symporter activityProton-coupled amino acid transporter 1Homo sapiens (human)
proline:proton symporter activityProton-coupled amino acid transporter 1Homo sapiens (human)
taurine transmembrane transporter activityProton-coupled amino acid transporter 1Homo sapiens (human)
protein bindingProton-coupled amino acid transporter 1Homo sapiens (human)
amino acid transmembrane transporter activityProton-coupled amino acid transporter 1Homo sapiens (human)
alanine transmembrane transporter activityProton-coupled amino acid transporter 1Homo sapiens (human)
L-alanine transmembrane transporter activityProton-coupled amino acid transporter 1Homo sapiens (human)
L-proline transmembrane transporter activityProton-coupled amino acid transporter 1Homo sapiens (human)
glycine transmembrane transporter activityProton-coupled amino acid transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (21)

Processvia Protein(s)Taxonomy
plasma membraneRap guanine nucleotide exchange factor 3Homo sapiens (human)
cortical actin cytoskeletonRap guanine nucleotide exchange factor 3Homo sapiens (human)
plasma membraneRap guanine nucleotide exchange factor 3Homo sapiens (human)
microvillusRap guanine nucleotide exchange factor 3Homo sapiens (human)
endomembrane systemRap guanine nucleotide exchange factor 3Homo sapiens (human)
membraneRap guanine nucleotide exchange factor 3Homo sapiens (human)
lamellipodiumRap guanine nucleotide exchange factor 3Homo sapiens (human)
filopodiumRap guanine nucleotide exchange factor 3Homo sapiens (human)
extracellular exosomeRap guanine nucleotide exchange factor 3Homo sapiens (human)
extracellular regionPlasminogenHomo sapiens (human)
extracellular spacePlasminogenHomo sapiens (human)
plasma membranePlasminogenHomo sapiens (human)
external side of plasma membranePlasminogenHomo sapiens (human)
cell surfacePlasminogenHomo sapiens (human)
platelet alpha granule lumenPlasminogenHomo sapiens (human)
collagen-containing extracellular matrixPlasminogenHomo sapiens (human)
extracellular exosomePlasminogenHomo sapiens (human)
blood microparticlePlasminogenHomo sapiens (human)
Schaffer collateral - CA1 synapsePlasminogenHomo sapiens (human)
glutamatergic synapsePlasminogenHomo sapiens (human)
extracellular spacePlasminogenHomo sapiens (human)
lysosomal membraneProton-coupled amino acid transporter 1Homo sapiens (human)
endoplasmic reticulumProton-coupled amino acid transporter 1Homo sapiens (human)
plasma membraneProton-coupled amino acid transporter 1Homo sapiens (human)
apical plasma membraneProton-coupled amino acid transporter 1Homo sapiens (human)
vacuolar membraneProton-coupled amino acid transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (137)

Assay IDTitleYearJournalArticle
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID1558616Plasma concentration in human at 100 mg/kg, po measured within 2 to 3 hrs2020Journal of medicinal chemistry, 02-27, Volume: 63, Issue:4
Fibrinolysis Inhibitors: Potential Drugs for the Treatment and Prevention of Bleeding.
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID496826Antimicrobial activity against Entamoeba histolytica2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID409954Inhibition of mouse brain MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID496823Antimicrobial activity against Trichomonas vaginalis2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496832Antimicrobial activity against Trypanosoma brucei rhodesiense2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1154949Binding affinity to full length Glu-plasminogen in human plasma assessed as inhibition of interaction with fibrin in presence of tPA2014ACS medicinal chemistry letters, May-08, Volume: 5, Issue:5
Discovery of the Fibrinolysis Inhibitor AZD6564, Acting via Interference of a Protein-Protein Interaction.
AID496820Antimicrobial activity against Trypanosoma brucei2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496829Antimicrobial activity against Leishmania infantum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1558615Drug level in human serum at 100 mg/kg, iv measured after 3 to 4 hrs2020Journal of medicinal chemistry, 02-27, Volume: 63, Issue:4
Fibrinolysis Inhibitors: Potential Drugs for the Treatment and Prevention of Bleeding.
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID255579Percent inhibition of CD40 expression in BCL1 cells treated with 1 uM peptide nucleic acid (PNA)conjugate; n=32005Journal of medicinal chemistry, Oct-20, Volume: 48, Issue:21
Structure-activity relationship study on a simple cationic peptide motif for cellular delivery of antisense peptide nucleic acid.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID595478Inhibition of mouse GAT2-mediated [3H]GABA uptake expressed in human HEK cells assessed as specific binding remaining at 1 mM2011European journal of medicinal chemistry, May, Volume: 46, Issue:5
Development of imidazole alkanoic acids as mGAT3 selective GABA uptake inhibitors.
AID409956Inhibition of mouse brain MAOB2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID496825Antimicrobial activity against Leishmania mexicana2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID595480Inhibition of mouse GAT4-mediated [3H]GABA uptake expressed in human HEK cells assessed as specific binding remaining at 1 mM2011European journal of medicinal chemistry, May, Volume: 46, Issue:5
Development of imidazole alkanoic acids as mGAT3 selective GABA uptake inhibitors.
AID255581Percent inhibition of CD40 expression in BCL1 cells treated with 3 uM peptide nucleic acid (PNA)conjugate; n=32005Journal of medicinal chemistry, Oct-20, Volume: 48, Issue:21
Structure-activity relationship study on a simple cationic peptide motif for cellular delivery of antisense peptide nucleic acid.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID496819Antimicrobial activity against Plasmodium falciparum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496830Antimicrobial activity against Leishmania major2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496827Antimicrobial activity against Leishmania amazonensis2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID595479Inhibition of mouse GAT3-mediated [3H]GABA uptake expressed in human HEK cells assessed as specific binding remaining at 1 mM2011European journal of medicinal chemistry, May, Volume: 46, Issue:5
Development of imidazole alkanoic acids as mGAT3 selective GABA uptake inhibitors.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID496828Antimicrobial activity against Leishmania donovani2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1558612Binding affinity to human plasminogen K1 domain by ultrafiltration technique2020Journal of medicinal chemistry, 02-27, Volume: 63, Issue:4
Fibrinolysis Inhibitors: Potential Drugs for the Treatment and Prevention of Bleeding.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1154948Binding affinity to human full length Glu-plasminogen in buffer assessed as inhibition of interaction with fibrin preincubated for 15 mins followed by thrombin addition measured every 2 mins for 15 hrs by Spectra-Max reader analysis in presence of tPA2014ACS medicinal chemistry letters, May-08, Volume: 5, Issue:5
Discovery of the Fibrinolysis Inhibitor AZD6564, Acting via Interference of a Protein-Protein Interaction.
AID255583Percent inhibition of CD40 expression in BCL1 cells treated with 10 uM peptide nucleic acid (PNA)conjugate; n=32005Journal of medicinal chemistry, Oct-20, Volume: 48, Issue:21
Structure-activity relationship study on a simple cationic peptide motif for cellular delivery of antisense peptide nucleic acid.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID496818Antimicrobial activity against Trypanosoma brucei brucei2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID496817Antimicrobial activity against Trypanosoma cruzi2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID630741Inhibition of human PAT1-mediated L-[3H]proline uptake in human Caco2 cells after 10 mins by liquid scintillation counting2011Bioorganic & medicinal chemistry, Nov-01, Volume: 19, Issue:21
Three-dimensional quantitative structure-activity relationship analyses of substrates of the human proton-coupled amino acid transporter 1 (hPAT1).
AID496824Antimicrobial activity against Toxoplasma gondii2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1558619Inhibition of plasmin (unknown origin) assessed as reduction in amidolytic activity2020Journal of medicinal chemistry, 02-27, Volume: 63, Issue:4
Fibrinolysis Inhibitors: Potential Drugs for the Treatment and Prevention of Bleeding.
AID1558614Initial serum concentration in human at 100 mg/kg, iv2020Journal of medicinal chemistry, 02-27, Volume: 63, Issue:4
Fibrinolysis Inhibitors: Potential Drugs for the Treatment and Prevention of Bleeding.
AID497005Antimicrobial activity against Pneumocystis carinii2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID144355In vitro inhibition of N8-Acetylspermidine deacetylase from rat liver cytosol(apparent Ki)1992Journal of medicinal chemistry, Jun-26, Volume: 35, Issue:13
Inhibition of N8-acetylspermidine deacetylase by active-site-directed metal coordinating inhibitors.
AID496831Antimicrobial activity against Cryptosporidium parvum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID595477Inhibition of mouse GAT1-mediated [3H]GABA uptake expressed in human HEK cells assessed as specific binding remaining at 1 mM2011European journal of medicinal chemistry, May, Volume: 46, Issue:5
Development of imidazole alkanoic acids as mGAT3 selective GABA uptake inhibitors.
AID496821Antimicrobial activity against Leishmania2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID1558617Half life in human2020Journal of medicinal chemistry, 02-27, Volume: 63, Issue:4
Fibrinolysis Inhibitors: Potential Drugs for the Treatment and Prevention of Bleeding.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB1996Biochemistry, Feb-27, Volume: 35, Issue:8
Crystal structures of the recombinant kringle 1 domain of human plasminogen in complexes with the ligands epsilon-aminocaproic acid and trans-4-(aminomethyl)cyclohexane-1-carboxylic Acid.
AID1811Experimentally measured binding affinity data derived from PDB1996Biochemistry, Feb-27, Volume: 35, Issue:8
Crystal structures of the recombinant kringle 1 domain of human plasminogen in complexes with the ligands epsilon-aminocaproic acid and trans-4-(aminomethyl)cyclohexane-1-carboxylic Acid.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1811Experimentally measured binding affinity data derived from PDB1999Biochemistry, Feb-16, Volume: 38, Issue:7
Recombinant kringle IV-10 modules of human apolipoprotein(a): structure, ligand binding modes, and biological relevance.
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB1999Biochemistry, Feb-16, Volume: 38, Issue:7
Recombinant kringle IV-10 modules of human apolipoprotein(a): structure, ligand binding modes, and biological relevance.
AID1345923Human plasminogen (S1: Chymotrypsin)2014ACS medicinal chemistry letters, May-08, Volume: 5, Issue:5
Discovery of the Fibrinolysis Inhibitor AZD6564, Acting via Interference of a Protein-Protein Interaction.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,613)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990752 (46.62)18.7374
1990's285 (17.67)18.2507
2000's243 (15.07)29.6817
2010's261 (16.18)24.3611
2020's72 (4.46)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 65.51

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index65.51 (24.57)
Research Supply Index7.56 (2.92)
Research Growth Index4.45 (4.65)
Search Engine Demand Index115.66 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (65.51)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials132 (7.36%)5.53%
Reviews157 (8.76%)6.00%
Case Studies196 (10.93%)4.05%
Observational6 (0.33%)0.25%
Other1,302 (72.62%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (25)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
The Effect of Intravenous E-Aminocaproic Acid (EACA) on Blood Loss and Transfusion Requirements After Bilateral Varus Rotational Osteotomy (VRO) [NCT02257580]Phase 428 participants (Actual)Interventional2015-04-01Completed
Randomized Clinical Trial to Verify the Effectiveness of Topical Aminocaproic Acid in the Prevention of Post-exodontic Bleeding in Patients on Anticoagulants [NCT02238288]Phase 4154 participants (Anticipated)Interventional2013-12-31Enrolling by invitation
Randomized Trial of Epsilon Aminocaproic Acid Versus Platelet Transfusions for the Prevention of Bleeding in Thrombocytopenic Patients With Hematological Malignancies [NCT02074436]Phase 229 participants (Actual)Interventional2014-05-23Terminated(stopped due to Slow accrual)
A Randomized, Single-Blinded, Placebo-Controlled Study Evaluating Postoperative Non-Opioid Pain Management Utilizing Local Anesthetics Coupled With Modulated Coagulation [NCT04814433]Phase 45 participants (Actual)Interventional2021-03-24Terminated(stopped due to Both lack of enrollment as well as study staff turnover)
A Pilot Study Comparing Anti-Inflammatory Effects Of Tranexamic Acid Versus Epsilon Aminocaproic Acid In Pediatric Congenital Heart Surgery [NCT02656472]Phase 422 participants (Actual)Interventional2016-02-29Completed
Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs [NCT04278404]5,000 participants (Anticipated)Observational2020-03-05Recruiting
A Pilot Study of Ultra-Early Intravenous ɛ-Aminocaproic Acid in Spontanteous Intracerebral Hemorrhage [NCT02639819]Phase 10 participants (Actual)Interventional2016-06-30Withdrawn(stopped due to Study was withdrawn from IRB review on 03/08/16)
Pharmacokinetics of Epsilon-Aminocaproic Acid in Children Undergoing Craniofacial Reconstruction Surgery [NCT00912119]Phase 118 participants (Actual)Interventional2009-05-31Completed
Oral Tranexamic Acid vs. Oral Aminocaproic Acid to Reduce Blood Loss, Transfusion Index and Complications After Total Hip Replacement. A Prospective, Randomized, Double Blind Clinical Trial [NCT04187014]Phase 290 participants (Actual)Interventional2020-02-06Completed
A Randomized Controlled Trial of Tranexamic Acid and ε-Aminocaproic Acid to Reduce Blood Loss Following Total Knee Arthroplasty [NCT01873768]Phase 4194 participants (Actual)Interventional2014-01-31Completed
The Effect of Standard vs Aggressive Dosing Regimens for Epsilon-aminocaproic Acid on a Quantifiable Parameter of Fibrinolysis as Measured by Thromboelastography [NCT01965730]Early Phase 18 participants (Actual)Interventional2013-01-31Terminated(stopped due to the study was suspended due to shortage of the study drug (amicar).)
Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care [NCT01431326]3,520 participants (Actual)Observational2011-11-30Completed
Efficacy of ε-Aminocaproic Acid (EACA) in Children Undergoing Craniofacial Reconstruction Surgery [NCT02229968]Phase 222 participants (Actual)Interventional2014-10-31Active, not recruiting
A Prospective, Randomized, Double-blinded Single-site Control Study Comparing Blood Loss Prevention of Tranexamic Acid (TXA) to Epsilon Aminocaproic Acid (EACA) for Corrective Spinal Surgery [NCT00958581]Phase 4177 participants (Actual)Interventional2008-12-31Completed
A Prospective, Randomized, Double Blind, Double-Dummy Study Comparing the Safety and Efficacy of Epsilon Aminocaproic Acid (eACA) Versus Tranexamic Acid (TXA) Versus Placebo for Prevention of Blood Loss in Total Knee Arthroplasty [NCT01527968]54 participants (Actual)Interventional2012-04-30Active, not recruiting
Jeanne Grace; Head Research Subjects Review Board [NCT00156520]Phase 440 participants (Anticipated)Interventional2005-03-31Completed
Fibrinolysis Before Cardiopulmonary Bypass? [NCT01981863]Phase 440 participants (Actual)Interventional2013-07-31Completed
Aminocaproic Acid and Bleeding in Spinal Surgery [NCT00320619]182 participants (Actual)Interventional2000-09-30Completed
Comparison of Tranexamic to Epsilon Aminocaproic Acid: a Prospective Analysis of Blood Conservation in Cardiac Surgery [NCT01248104]100 participants (Actual)Interventional2010-03-31Completed
Activated Factor Seven (aFVII) Versus Aminocaproic Acid For Treatment of Traumatic Retro-Peritoneal Hematoma [NCT04424563]80 participants (Actual)Observational [Patient Registry]2017-05-05Completed
Bradykinin Receptor Antagonism During Cardiopulmonary Bypass [NCT00223704]Phase 2/Phase 3150 participants (Actual)Interventional2006-05-31Completed
A Single Site Evaluation of the Effect of Topical Application of Aminocaproic Acid (ACA) to Inhibit Kallikrein 5 Serine Protease Activity and Production of LL-37 Cathelicidin Peptide, Biochemical Markers of Rosacea-specific Inflammation. [NCT01398280]Early Phase 115 participants (Actual)Interventional2011-07-31Completed
A Randomized, Double-blinded Trial Comparing the Efficacy of Tranexamic Acid and Epsilon-aminocaproic Acid in Reducing Bleeding and Transfusions in Cardiac Surgery [NCT02655653]Phase 3114 participants (Actual)Interventional2008-10-31Completed
TXA (Tranexamic Acid) vs. Amicar (Aminocaproic Acid) in Total Knee and Hip Arthroplasty- Effectiveness, Safety, and Cost Analysis [NCT02030821]Phase 4246 participants (Actual)Interventional2015-01-31Completed
Comparative Study of the Efficiency of Oral Tranexamic Tcid vs. Oral Tminocaproic Acid to Reduce Blood Loss and Transfusion After Total Knee Replacement. A Prospective, Randomized, Double Blinded Controlled Clinical Trial. [NCT03365999]Phase 292 participants (Actual)Interventional2017-10-15Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00223704 (5) [back to overview]Units of Packed Red Blood Cells Transfused During Hospitalization
NCT00223704 (5) [back to overview]Units of Plasma Transfused During Hospitalization
NCT00223704 (5) [back to overview]Allogenic Blood Product Transfusion Risk
NCT00223704 (5) [back to overview]Fibrinolytic Response as Measured by D-dimer
NCT00223704 (5) [back to overview]Inflammatory Response as Measured by Interleukin-6
NCT00958581 (1) [back to overview]Total Blood Loss Over Course of Stay (Intraoperative and Postoperatively Until Discharge)
NCT01248104 (1) [back to overview]Total Transfusion Amounts
NCT01398280 (1) [back to overview]Kallikrein 5 (KLK5) Protease Activity
NCT01981863 (3) [back to overview]Length of Time Between Incision and Cardiopulmonary Bypass
NCT01981863 (3) [back to overview]Di-Dimer Increase Before Cardiopulmonary Bypass
NCT01981863 (3) [back to overview]Value of Thromboelastography as Monitor of Fibrinolysis
NCT02030821 (4) [back to overview]Difference in Preoperative and Lowest Postoperative Hemoglobin
NCT02030821 (4) [back to overview]Length of Hospitalization Stay
NCT02030821 (4) [back to overview]Number of Transfusions
NCT02030821 (4) [back to overview]Total Blood Loss Over Course of Stay (Intraoperative and Postoperatively Until Discharge)
NCT02074436 (1) [back to overview]Percentage of Participants Who Develop Major Bleeding Episodes
NCT02257580 (6) [back to overview]Complications [VTE (Symptomatic of DVT or PE), Infection (Superficial, Deep), Hematoma, Seroma, Reoperation, and Death]
NCT02257580 (6) [back to overview]Intraoperative Calculated Total Blood Loss
NCT02257580 (6) [back to overview]Intraoperative Cell Saver Utilization
NCT02257580 (6) [back to overview]Length of Hospital Stay
NCT02257580 (6) [back to overview]Post Operative Blood Loss
NCT02257580 (6) [back to overview]Postoperative Allogeneic Blood Transfusion
NCT02655653 (9) [back to overview]Diagnosis of Myocardial Infarction Post-operation
NCT02655653 (9) [back to overview]Diagnosis of Renal Dysfunction Post-operation
NCT02655653 (9) [back to overview]Median Amount of Blood Products Used
NCT02655653 (9) [back to overview]Mortality Within 30 Days Post-operation
NCT02655653 (9) [back to overview]Number of Participants Who Have Confirmed Diagnosis of Respiratory Arrest
NCT02655653 (9) [back to overview]Number of Participants With Confirmed Diagnosis of Seizure
NCT02655653 (9) [back to overview]Number of Participants With Confirmed Diagnosis of Stroke
NCT02655653 (9) [back to overview]Reoperation
NCT02655653 (9) [back to overview]Chest Tube Drainage

Units of Packed Red Blood Cells Transfused During Hospitalization

Units of Packed Red Blood Cells Transfused (NCT00223704)
Timeframe: Patients were followed for the duration of hospital stay, an average of 6 days

Interventionunits (Mean)
Placebo Group1.97
Aminocaproic Acid Group1.41
HOE 140 Group1.45

[back to top]

Units of Plasma Transfused During Hospitalization

Units of plasma transfused (NCT00223704)
Timeframe: Patients were followed for the duration of hospital stay, an average of 6 days

Interventionunits (Mean)
Placebo Group1.08
Aminocaproic Acid Group0.68
HOE 140 Group0.82

[back to top]

Allogenic Blood Product Transfusion Risk

Blood product transfusion during hospitalization that included packed red blood cells, plasma, platelets and cryoprecipitate. (NCT00223704)
Timeframe: Patients were followed for the duration of hospital stay, an average of 6 days

,,
Interventionpercentage of participants (Number)
Received any transfusionReceived packed red blood cellsReceived plasmaReceived plateletsReceived cryoprecipitate
Aminocaproic Acid Group56.848.624.316.22.7
HOE 140 Group52.547.517.517.55.0
Placebo Group47.436.831.623.710.5

[back to top]

Fibrinolytic Response as Measured by D-dimer

D-dimer concentrations were measured at baseline, 30min and 60min of bypass, post-bypass and postoperative day 1 (NCT00223704)
Timeframe: Patients were followed from the start of surgery until postoperative day 1

,,
Interventionng/ml (Mean)
Baseline30min of bypass60min of bypassPost-bypassPostoperative day 1
Aminocaproic Acid Group103.0131.9154.3168.9269.5
HOE 140 Group88.1209.0363.3858.5337.3
Placebo Group95.5150.6287.6589.8390.4

[back to top]

Inflammatory Response as Measured by Interleukin-6

Interleukin-6 was measured at baseline, post-bypass and on postoperative day 1 and 2. (NCT00223704)
Timeframe: Patients were followed from the start of surgery until postoperative day 2

,,
Interventionpg/ml (Mean)
BaselinePost-bypassPostoperative day 1Postoperative day 2
Aminocaproic Acid Group6.5864.65161.91122.88
HOE 140 Group4.80142.02166.2786.54
Placebo Group4.9868.8118.8201.5

[back to top]

Total Blood Loss Over Course of Stay (Intraoperative and Postoperatively Until Discharge)

(NCT00958581)
Timeframe: 1 Week

Interventionml (Mean)
Epsilon Aminocaproic Acid1775
Normal Saline2116
Tranexamic Acid1531

[back to top]

Total Transfusion Amounts

The outcome measure was the intergroup difference in total transfusion amounts up to post-operative day 2. (NCT01248104)
Timeframe: 48 hours

Interventionmililiters (Mean)
Tranexamic Acid161
Aminocaproic Acid116

[back to top]

Kallikrein 5 (KLK5) Protease Activity

Serine protease activity of KLK5 in adult skin from patients with rosacea is measured after treatment with vehicle or aminocaproic acid cream. Protease activity of facial skin surface is monitored using a synthetic fluorogenic trypsin-like proteinase substrate. Protease activity is monitored as an increase of fluorescence (RFU/uL) with SpectraMax GEMINI EM. (NCT01398280)
Timeframe: Up to 12 weeks

InterventionRFU/uL (Mean)
Aminocaproic Acid (ACA)581.1
Vehicle Cream816.5

[back to top]

Length of Time Between Incision and Cardiopulmonary Bypass

Mean Length of Time from Incision to Cardiopulmonary Bypass (NCT01981863)
Timeframe: From incision to bypass, up to 3 hours

InterventionMinutes (Mean)
Epsilonaminocaproic Acid140
Placebo, Antifibrinolytic Activity165

[back to top]

Di-Dimer Increase Before Cardiopulmonary Bypass

Change in Di-dimer between preoperative value and value immediately before cardiopulmonary bypass in cardiac surgery patients. (NCT01981863)
Timeframe: 6 months

,
Interventionng/mL (Median)
Preoperative ValueImmediately Before Cardiopulmonary BypassPost cardiopulmonary bypass
Epsilonaminocaproic Acid317317537
Placebo, Antifibrinolytic Activity266291911

[back to top]

Value of Thromboelastography as Monitor of Fibrinolysis

Thromboelastography may display if fibrinolysis is present (NCT01981863)
Timeframe: 6 months

,
Interventionpercentage of clot (Median)
Preoperative Estimated Plasma LysisEstimated Plasma Lysis Prior to BypassEstimated Plasma Lysis Post Bypass
Epsilonaminocaproic Acid000
Placebo, Antifibrinolytic Activity000

[back to top]

Difference in Preoperative and Lowest Postoperative Hemoglobin

(NCT02030821)
Timeframe: Participants will be followed for the duration of hospital stay, an expected average of 5 days

Interventiongrams per deciliter (Median)
Tranexamic Acid (TXA) - Total Hip Arthroplasty2.4
Epsilon-aminocaproic Acid (Amicar)2.6
Tranexamic Acid (TXA) - Total Knee Arthroplasty1.9
Epsilon-aminocaproic Acid (Amicar) - Total Knee Arthroplasty2.1

[back to top]

Length of Hospitalization Stay

(NCT02030821)
Timeframe: Participants will be followed for the duration of hospital stay, an expected average of 5 days

Interventiondays (Median)
Tranexamic Acid (TXA) - Total Hip Arthroplasty2.5
Epsilon-aminocaproic Acid (Amicar)3
Tranexamic Acid (TXA) - Total Knee Arthroplasty3
Epsilon-aminocaproic Acid (Amicar) - Total Knee Arthroplasty3

[back to top]

Number of Transfusions

(NCT02030821)
Timeframe: Participants will be followed for the duration of hospital stay, an expected average of 5 days

Interventiontransfusions (Number)
Tranexamic Acid (TXA) - Total Hip Arthroplasty0
Epsilon-aminocaproic Acid (Amicar)0
Tranexamic Acid (TXA) - Total Knee Arthroplasty0
Epsilon-aminocaproic Acid (Amicar) - Total Knee Arthroplasty1

[back to top]

Total Blood Loss Over Course of Stay (Intraoperative and Postoperatively Until Discharge)

(NCT02030821)
Timeframe: Participants will be followed for the duration of hospital stay, an expected average of 5 days

Interventionmilliliters (Median)
Tranexamic Acid (TXA) - Total Hip Arthroplasty934.1
Epsilon-aminocaproic Acid (Amicar)948.7
Tranexamic Acid (TXA) - Total Knee Arthroplasty660.6
Epsilon-aminocaproic Acid (Amicar) - Total Knee Arthroplasty891.2

[back to top]

Percentage of Participants Who Develop Major Bleeding Episodes

"The primary objective of this study is to compare the percentage of patients who develop major bleeding episodes (WHO grades 3-4) in the group randomized to receive prophylactic EACA versus standard of care prophylactic platelet transfusions.~Grade 3 bleeding is defined as a bleed that significantly limits the patient's ability to perform routine activities despite symptomatic therapy and leads to reduction of the dose or discontinuation of the study drug.~Grade 4 bleeding is a life-threatening bleed that requires discontinuation of the study drug and the patient is at immediate risk of death" (NCT02074436)
Timeframe: 6 months

,
InterventionParticipants (Count of Participants)
Grade 3 BleedingGrade 4 Bleeding
Platelet Transfusion110
Prophylactic EACA011

[back to top]

Complications [VTE (Symptomatic of DVT or PE), Infection (Superficial, Deep), Hematoma, Seroma, Reoperation, and Death]

Incidence of VTE (symptomatic of DVT or PE), infection (superficial, deep), hematoma, seroma, reoperation, and death, measured in person-years ( x cases per 100,000 person years) (NCT02257580)
Timeframe: an expected average of 1 week (post-surgery), Follow-up at 6 weeks

Interventioncases per 100,000 person years (Number)
E-Aminocaproic Acid (EACA)0
Placebo0

[back to top]

Intraoperative Calculated Total Blood Loss

Determined by estimated blood volume, calculated using difference in preoperative and postoperative hemoglobin and applied to the Nadler equation for estimating blood volume while adjusting for transfused hemoglobin to produce a single metric of calculated intraoperative blood loss. (NCT02257580)
Timeframe: Intraoperative (3-6 hours)

InterventionmL (Mean)
E-Aminocaproic Acid (EACA)535.7
Placebo628.0

[back to top]

Intraoperative Cell Saver Utilization

Number of participants requiring 1 unit of intraoperative cell saver transfusion. Patients either received or did not receive intraoperative cell saver transfusion. The maximum number of intraoperative units transfused in this study was 1 unit. The count of participants in the data table refers to the number of patients who received this transfusion. (NCT02257580)
Timeframe: Intraoperative, 1 day

InterventionParticipants (Count of Participants)
E-Aminocaproic Acid (EACA)7
Placebo7

[back to top]

Length of Hospital Stay

postoperative day of discharge after surgery- day of intake. (NCT02257580)
Timeframe: Post-Surgery, an expected average of 1 week

Interventiondays (Mean)
E-Aminocaproic Acid (EACA)5.5
Placebo5.1

[back to top]

Post Operative Blood Loss

24 hour drain output (mL) (NCT02257580)
Timeframe: Post-Surgery, 24 hours

InterventionmL (Mean)
E-Aminocaproic Acid (EACA)72.5
Placebo103.3

[back to top]

Postoperative Allogeneic Blood Transfusion

The number of participants that required 1 unit of blood transfused post-operatively. Patients received blood if necessary post operatively, and the maximum number of units a patient received was 1. The count of participants refers to the number of patients who received this transfusion unit. (NCT02257580)
Timeframe: Post-Surgery, an expected average of 1 week

InterventionParticipants (Count of Participants)
E-Aminocaproic Acid (EACA)4
Placebo3

[back to top]

Diagnosis of Myocardial Infarction Post-operation

Confirmed diagnosis of myocardial infraction and hospitalization for the same within 30 days after the surgery (NCT02655653)
Timeframe: Within 30 days after surgery

InterventionParticipants (Count of Participants)
Epsilon-aminocaproic Acid (EACA)1
Tranexamic Acid (TA)1

[back to top]

Diagnosis of Renal Dysfunction Post-operation

Confirmed diagnosis of renal dysfunction and hospitalization for the same within 30 days after the surgery (NCT02655653)
Timeframe: Within 30 days after surgery

InterventionParticipants (Count of Participants)
Epsilon-aminocaproic Acid (EACA)3
Tranexamic Acid (TA)2

[back to top]

Median Amount of Blood Products Used

Four types of blood products may be given through blood transfusions: whole blood, red blood cells, platelets, and plasma (NCT02655653)
Timeframe: 24 hours after surgery

InterventionL (Median)
Epsilon-aminocaproic Acid (EACA).59
Tranexamic Acid (TA)1.20

[back to top]

Mortality Within 30 Days Post-operation

(NCT02655653)
Timeframe: Within 30 days after surgery

InterventionParticipants (Count of Participants)
Epsilon-aminocaproic Acid (EACA)1
Tranexamic Acid (TA)1

[back to top]

Number of Participants Who Have Confirmed Diagnosis of Respiratory Arrest

Confirmed diagnosis of respiratory arrest and hospitalization for the same within 30 days after the surgery (NCT02655653)
Timeframe: Within 30 days after surgery

InterventionParticipants (Count of Participants)
Epsilon-aminocaproic Acid (EACA)11
Tranexamic Acid (TA)5

[back to top]

Number of Participants With Confirmed Diagnosis of Seizure

Confirmed diagnosis of seizure and hospitalization for the same within 30 days after the surgery (NCT02655653)
Timeframe: Within 30 days after surgery

InterventionParticipants (Count of Participants)
Epsilon-aminocaproic Acid (EACA)0
Tranexamic Acid (TA)0

[back to top]

Number of Participants With Confirmed Diagnosis of Stroke

Confirmed diagnosis of stroke and hospitalization for the same within 30 days after the surgery (NCT02655653)
Timeframe: Within 30 days after surgery

InterventionParticipants (Count of Participants)
Epsilon-aminocaproic Acid (EACA)2
Tranexamic Acid (TA)2

[back to top]

Reoperation

Confirmed diagnosis of reopeartion and hospitalization for the same within 30 days after the surgery (NCT02655653)
Timeframe: Within 30 days after surgery

InterventionParticipants (Count of Participants)
Epsilon-aminocaproic Acid (EACA)3
Tranexamic Acid (TA)4

[back to top]

Chest Tube Drainage

Chest tube drainage are collected from the nursing records, every 4th hourly the amount fluid collected is reported in the collection sheets. (NCT02655653)
Timeframe: 4 hours, 8 hours, 12 hours, 24 hours

,
InterventionmL (Mean)
4 hr8 hr12 hr24 hr
Epsilon-aminocaproic Acid (EACA)200375425700
Tranexamic Acid (TA)225400500800

[back to top]